Lexicon Pharmaceuticals, Inc.: Q4 FY2025 earnings call

What management said about Q4 FY2025, from the documents filed with the SEC on 5 March 2026: press release. The quarter’s numbers.

Read the filing

Key takeaways

• Revenue rose on Novo licensing payment: Full-year 2025 total revenues were $49.8 million, against $31.1 million in 2024. Licensing revenue of $45 million from Novo Nordisk made up most of the year's total. Source
• Net loss below prior-year levels: Q4 2025 net loss was $15.5 million, or $0.04 per share, against $33.8 million, or $0.09 per share in Q4 2024. Full-year net loss was $50.3 million, or $0.14 per share, against $200.4 million, or $0.63. Source
• SONATA-HCM enrollment past half: SONATA-HCM, a pivotal placebo-controlled Phase 3 study with a 500-patient target, has surpassed 50 percent enrollment across 130 sites in 20 countries. Source
• Pilavapadin cleared for Phase 3 design: The FDA raised no objections to advancing pilavapadin into Phase 3 after the Q4 2025 End-of-Phase 2 meeting. Planned design is two placebo-controlled, 12-week studies at 10 mg daily; the primary endpoint is change in average daily pain score. Source
• ZYNQUISTA timing tied to STENO1 data: Lexicon's ZYNQUISTA path depends on FDA-identified patient exposure and safety data requirements being met through STENO1, a third-party funded study of sotagliflozin. Source
• R&D spend fell after PROGRESS trial: R&D expense was $11.3 million in Q4 2025, against $26.7 million, and $61.1 million for 2025, against $84.5 million. Lower PROGRESS external research was partly offset by SONATA investment. Source
• Cash fell during 2025: Cash, investments and restricted cash were $125.2 million at December 31, 2025, against $238.0 million in cash and investments a year earlier. Restricted cash was $29.0 million. Source
• Partnership talks for pilavapadin: Management said Lexicon continues partnership discussions to maximize the global potential of pilavapadin, following the End-of-Phase 2 meeting. Source

“The fourth quarter of 2025 marked the completion of an incredible year for Lexicon,”

Mike Exton, Ph.D., Lexicon’s chief executive officer and director

Guidance

What changed from last quarter

• New: The January 2026 proposed common stock offering was followed in February by about $96.7 million of net proceeds from common and preferred stock sales. Source
• New: Lexicon received a $10 million milestone payment from Novo Nordisk in February 2026. Source
• New: Lexicon and the FDA held an End-of-Phase 2 meeting for pilavapadin in the fourth quarter of 2025, with no FDA objection to Phase 3 advancement. Source
• New: The first commercial sotagliflozin product was shipped to the United Arab Emirates in 2025, the first country to approve it outside the U.S. Source

Results and growth drivers

• Revenue rose on Novo licensing payment: Full-year 2025 total revenues were $49.8 million, against $31.1 million in 2024. Licensing revenue of $45 million from Novo Nordisk made up most of the year's total. Source
• Net loss below prior-year levels: Q4 2025 net loss was $15.5 million, or $0.04 per share, against $33.8 million, or $0.09 per share in Q4 2024. Full-year net loss was $50.3 million, or $0.14 per share, against $200.4 million, or $0.63. Source
• Stock-based compensation totals: Non-cash stock-based compensation was $2.8 million in Q4 2025 and $12.5 million for 2025, against $1.5 million and $13.5 million in 2024. Source

Pipeline milestones and trials

• SONATA-HCM enrollment past half: SONATA-HCM, a pivotal placebo-controlled Phase 3 study with a 500-patient target, has surpassed 50 percent enrollment across 130 sites in 20 countries. Source
• Pilavapadin cleared for Phase 3 design: The FDA raised no objections to advancing pilavapadin into Phase 3 after the Q4 2025 End-of-Phase 2 meeting. Planned design is two placebo-controlled, 12-week studies at 10 mg daily; the primary endpoint is change in average daily pain score. Source
• ZYNQUISTA timing tied to STENO1 data: Lexicon's ZYNQUISTA path depends on FDA-identified patient exposure and safety data requirements being met through STENO1, a third-party funded study of sotagliflozin. Source
• LX9851 IND-enabling work completed: Management said all IND application-enabling activities for LX9851 were completed by Lexicon in 2025. Novo Nordisk is developing LX9851 for obesity and weight management. Source

“we have begun 2026 with tremendous momentum and are well-positioned to successfully execute on multiple important catalysts ahead.”

Mike Exton, Ph.D., Lexicon’s chief executive officer and director

Partnered programs and licensees

• Viatris launches first ex-U.S. market: Viatris, licensee outside the U.S. and Europe, shipped the first commercial sotagliflozin product to the UAE in 2025, the first non-U.S. approval. Source
• Viatris filings in more markets: Viatris applied in several markets in 2025, including Canada, Australia and New Zealand, and is preparing further submissions in additional ex-U.S. and ex-European markets in 2026. Source
• Novo deal terms for LX9851: Novo Nordisk paid a $45 million upfront in April 2025. Lexicon is eligible for up to $1 billion in milestones and tiered royalties on LX9851 net sales. Source

Product sales

• INPEFA sales lower year on year: INPEFA net sales were $1.1 million in Q4 2025 and $4.6 million for 2025, against $1.6 million and $6.0 million in 2024. Source
• ZYNQUISTA focus remains T1D: Management said it remains focused on bringing ZYNQUISTA to market for glycemic control in adults with T1D, a population without a new mechanism since insulin. Source
• Royalties and other revenue small: Royalties and other revenue was $136 thousand in Q4 2025 and $156 thousand for 2025, against $4 thousand and $80 thousand in 2024. Source

“Over the past year, we have pulled multiple levers to strengthen our financial position and extend our cash runway to support our robust clinical development pipeline.”

Scott Coiante, Lexicon’s senior vice president and chief financial officer

Operating costs

• R&D spend fell after PROGRESS trial: R&D expense was $11.3 million in Q4 2025, against $26.7 million, and $61.1 million for 2025, against $84.5 million. Lower PROGRESS external research was partly offset by SONATA investment. Source
• SG&A fell with repositioning: SG&A was $8.8 million in Q4 2025, against $32.3 million, and $37.3 million for 2025, against $143.1 million in 2024. Source
• Total operating expenses declined: Total operating expenses were $20.3 million in Q4 2025 and $98.7 million for 2025, against $59.3 million and $228.2 million. Loss from operations was $48.9 million for 2025. Source

Cash, debt and equity

• Cash fell during 2025: Cash, investments and restricted cash were $125.2 million at December 31, 2025, against $238.0 million in cash and investments a year earlier. Restricted cash was $29.0 million. Source
• Debt reduced year on year: Debt was $4.6 million current and $49.4 million long-term at December 31, 2025, against $100.3 million long-term debt and no current portion a year earlier. Source
• Stockholders' equity lower: Total stockholders’ equity was $107.5 million at December 31, 2025, against $145.9 million, with an accumulated deficit of $2.0 billion. Source

Strategy and partnerships

• Partnership talks for pilavapadin: Management said Lexicon continues partnership discussions to maximize the global potential of pilavapadin, following the End-of-Phase 2 meeting. Source
• Pilavapadin potential as first oral option: Management describes pilavapadin as having potential to be the first oral, non-opioid drug therapy approved in neuropathic pain in more than 20 years. Source
• Lower costs tied to repositioning: Management attributes lower 2025 costs to a strategic repositioning in late 2024 and to significantly reduced INPEFA marketing and promotion in 2025. Source

Coming up, as management said on 5 March 2026

• Pilavapadin Phase 3 studies planned: Management said the planned Phase 3 program would include two registrational studies comparing pilavapadin 10 mg daily to placebo. Source
• SONATA-HCM topline readout: Management expects SONATA-HCM topline results after enrollment completion, with topline timing set for the first quarter of 2027. Source

Figures management reported

Risks management discussed

• Regulatory: ZYNQUISTA NDA resubmission and 2026 approval depend on FDA-identified patient exposure and safety data being achieved through STENO1, a third-party funded study. Source

Earlier plans management reported on

• On track: The headline says pivotal sotagliflozin milestones are on schedule, including NDA resubmission in T1D and enrollment of SONATA. Source
• Met: Management said all IND application-enabling activities for LX9851 were completed in 2025. Source
• On track: Management said it remains on track for potential NDA resubmission and regulatory approval in 2026. Source

Other quarters

• Q3 FY2026 earnings call
• Q2 FY2026 earnings call
• Q1 FY2026 earnings call
• Q3 FY2025 results

Summarised with AI from the documents the company filed with the SEC. Every point is checked against the filing before it is shown: management’s own words word for word, figures against the line or table row they come from. A point that fails the check is left out. Source opens the filing at that line.